Sort by
Items per page

Send to

Choose Destination

Search results

Items: 7


Drowning Management.

Parenteau M, Stockinger Z, Hughes S, Hickey B, Mucciarone J, Manganello C, Beeghly A.

Mil Med. 2018 Sep 1;183(suppl_2):172-179. doi: 10.1093/milmed/usy136.


IGF-II promoter methylation and ovarian cancer prognosis.

Beeghly AC, Katsaros D, Wiley AL, Rigault de la Longrais IA, Prescott AT, Chen H, Puopolo M, Rutherford TJ, Yu H.

J Cancer Res Clin Oncol. 2007 Oct;133(10):713-23. Epub 2007 Jun 14.


Aberrant promoter methylation of multiple genes in malignant ovarian tumors and in ovarian tumors with low malignant potential.

Wiley A, Katsaros D, Chen H, Rigault de la Longrais IA, Beeghly A, Puopolo M, Singal R, Zhang Y, Amoako A, Zelterman D, Yu H.

Cancer. 2006 Jul 15;107(2):299-308.


Glutathione S-transferase polymorphisms and ovarian cancer treatment and survival.

Beeghly A, Katsaros D, Chen H, Fracchioli S, Zhang Y, Massobrio M, Risch H, Jones B, Yu H.

Gynecol Oncol. 2006 Feb;100(2):330-7. Epub 2005 Sep 29.


African-American/White differences in breast carcinoma: p53 alterations and other tumor characteristics.

Jones BA, Kasl SV, Howe CL, Lachman M, Dubrow R, Curnen MM, Soler-Vila H, Beeghly A, Duan F, Owens P.

Cancer. 2004 Sep 15;101(6):1293-301.


Mouse Gli1 mutants are viable but have defects in SHH signaling in combination with a Gli2 mutation.

Park HL, Bai C, Platt KA, Matise MP, Beeghly A, Hui CC, Nakashima M, Joyner AL.

Development. 2000 Apr;127(8):1593-605.


Toward the construction of integrated physical and genetic maps of the mouse genome using interspersed repetitive sequence PCR (IRS-PCR) genomics.

Hunter KW, Riba L, Schalkwyk L, Clark M, Resenchuk S, Beeghly A, Su J, Tinkov F, Lee P, Ramu E, Lehrach H, Housman D.

Genome Res. 1996 Apr;6(4):290-9.

Supplemental Content

Loading ...
Support Center